Jade Biosciences Inc. (JBIO)
JBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | JBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001798749 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $80.4M cash; operating cash flow -$32.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 69,189,448 (2026-11-06); 46,004,205 a year earlier; 27,668,887 three years earlier. 3y figure adjusted for split (1-for-35 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-35 on 2025-04-29 | Source 2025-04-29 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$35.1M | -$28.9M | $80.4M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | Not filed | -$55.8M | -$43.7M | $107.3M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q1 2026 2026-03-31 | Not filed | -$40.4M | -$24.1M | $55.1M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q4 2025 2025-12-31 | Not filed | -$31.9M | -$33.6M | $88.4M | No debt tags | Needs four quarters | 10-K 2026-03-06 |
| Q3 2025 2025-09-30 | Not filed | -$25.2M | -$22.1M | $50.1M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$32.1M | -$20.2M | $220.9M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q1 2025 2025-03-31 | Not filed | -$38.2M | -$18.8M | $44.2M | No debt tags | Needs four quarters | 10-Q 2026-11-13 |
| Q4 2024 2024-12-31 | Not filed | -$5.4M | -$11.0M | $69.4M | No debt tags | Needs four quarters | 10-K 2025-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-04 |
| Latest annual report | 10-K | 2026-03-06 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-06-05 |
Source: SEC EDGAR submissions feed, 515 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.1% |
| 1 month | +20.3% |
| 3 months | -32.2% |
| Year to date | +4.6% |
| 1 year | +66.7% |
| From 52-week high | -39.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VSTM | Verastem Inc. | $7.70 | -5.87% | $970.3M |
| SVRA | Savara Inc. | $4.46 | -3.77% | $985.1M |
| MLTX | MoonLake Immunotherapeutics | $11.73 | -6.16% | $998.3M |
| CYRX | CryoPort Inc. | $19.80 | -0.45% | $1.0B |
| SPTX | Seaport Therapeutics Inc. | $19.12 | -4.30% | $1.0B |
| MTRI | Mentari Therapeutics Inc. | $19.87 | +6.83% | $1.0B |
| AKTS | Aktis Oncology Inc. | $16.16 | -2.77% | $901.7M |
| CRVS | Corvus Pharmaceuticals Inc. | $10.60 | -0.38% | $894.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier